Medicine optimisation
Adherence
Aide raises adherence to avg. 73.3% for ICS prescriptions, paving the way for a >10% reduction in severe exacerbations
Inhaled corticosteroids (ICS) adherence in adults (using the Medication Possession Rate), ranges between 15% and 54%. Increasing adherence by 25% has been associated with an approximately 10% reduction in severe exacerbations.1
Managing polypharmacy
Avg. 3.62 medicines
Patients manage a mean of 3.62 prescribed medicines (range: 1–19), reflecting substantial polypharmacy within the population.
Supporting common medicines
Atorvastatin, amlodipine and metformin
Three most common medicines managed in Aide, reflecting its reach across cardiovascular and metabolic conditions.
Engagement
Retention rate
Aide achieves 30-day retention rate of over 70%, approximately 18x industry average2
Retention is measured using a rolling monthly cohort analysis, a stringent standard for assessing sustained engagement. Many patients continue to use Aide daily for more than two years, demonstrating long-term behaviour change.
Interactions
Avg. 4 conversations
With Aide per patient per day. Over 80× more than the average number of annual GP interactions among multi-morbid patients3.
Onboarding time
Under 10 minutes
Mean duration for patients to complete onboarding, from registration, through consent and medicine entry.
Cost reduction
Saving clinical time
332.3 hours and £19.2k saved per 1,000 asthma patients via asynchronous education
As few as 25% of people typically demonstrate correct inhaler technique.4 Aide delivered conversation-based education on inhaler technique to 31 patients who needed it in Suffolk Primary Care, saving 10.3 clinical hours.
Reducing unplanned care
Confidence and activation reduce avoidable GP visits, emergency attendances, and hospital admissions
Higher levels of patient activation are associated with measurable reductions in utilisation. Evidence from studies using the Patient Activation Measure (PAM) shows that more confident, capable patients are less likely to require unplanned care5.
+7.4%
Increase in confidence in the skills and capability to manage my condition
+8.4%
Increase in understanding what my medications are for, and can take them as prescribed.
+4.2%
Increased in feeling fully involved in decisions about my treatment and lifestyle advice
+8.4%
Increase in confidence I can work out what to do if my condition changes in the future
Stratifying risk
Unmanaged risk
Aide identifies 50% of patients who do not have an asthma action plan (AAP)
AAP use is associated with a 70% reduction in mortality6. By identifying patients without an AAP, Aide enables earlier intervention and targeted support, addressing a critical gap in self-management and safety.
Managing polypharmacy
Aide detects reliever inhaler overuse (>2 times per week), reasons for overuse, and delivers education on reliever and preventer use
Reliever inhaler overuse puts people at increased risk of hospitalisation7 and is indicative of poor asthma control. Identifying these patients and providing an intervention could save £1516 to £2473 per patient8.
Health equity
Age inclusion
Used by patients aged 18 to 87
Aide engages patients across generations, with a median age of 52, showing adoption among those often excluded from digital health.
Regional inclusion
Supporting areas of deprivation
Deployed in regions classified as ‘hard pressed ageing workers’, ‘rural tenants’, and ‘outer city hardship’, reaching underserved populations.
